CLL1 + CD33 + CD38 + CD7 CAR-T

This is a multi-target chimeric antigen receptor T cell (CAR-T) therapy engineered to recognize and attack cells expressing any of the following antigens commonly found in acute myeloid leukemia (AML): CLL1 (CLEC12A), CD33, CD38, and CD7. Each of these antigens is associated with different AML cell populations, including leukemia stem cells (CLL1), bulk disease cells (CD33), and other subpopulations that may contribute to disease persistence or relapse (CD38, CD7). By targeting multiple antigens simultaneously, this CAR-T approach aims to overcome tumor heterogeneity and reduce the risk of antigen escape—a major limitation of single-antigen CAR-T therapies. The therapy involves genetically modifying patient-derived T-cells to express synthetic receptors specific for these four targets. This strategy has shown promise in preclinical studies and early-phase clinical trials for relapsed/refractory AML by eradicating both leukemia blasts and stem cells while potentially minimizing toxicity compared to traditional ablation regimens[1][2][6][7].

Other names

CLL1 + CD33 + CD38 + CD7 CAR-T